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To determine whether acute renal failure (ARF) increases the
long-term risk of progressive chronic kidney disease (CKD), we
studied the outcome of patients whose initial kidney function
was normal or near normal but who had an episode of dialysis-
requiring ARF and did not develop end-stage renal disease
within 30 days following hospital discharge. The study
encompassed 556,090 adult members of Kaiser Permanente of
Northern California hospitalized over an 8 year period, who
had pre-admission estimated glomerular filtration rates (eGFR)
equivalent to or greater than 45ml/min/1.73m2 and who
survived hospitalization. After controlling for potential
confounders such as baseline level of eGFR and diabetes status,
dialysis-requiring ARF was independently associated with a
28-fold increase in the risk of developing stage 4 or 5 CKD and
more than a twofold increased risk of death. Our study shows
that in a large, community-based cohort of patients with
pre-existing normal or near normal kidney function, an episode
of dialysis-requiring ARF was a strong independent risk factor
for a long-term risk of progressive CKD and mortality.
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Acute renal failure (ARF) (also known as acute kidney injury)
is one of the most important complications among
hospitalized patients. ARF severe enough to require dialysis
is associated with a high rate of in-hospital death.1,2 The
public health importance of ARF is highlighted by recent
reports that its incidence is increasing.3–5
Most studies on ARF have focused on short-term in-
hospital outcomes,6–10 and the literature is rather limited
with regard to the long-term sequelae of ARF. A number of
older publications indicated that kidney function often
recovered to such an extent after ARF that long-term dialysis
was not required,11–13 but these were conducted decades ago
when the patient population suffering from ARF was very
different. A recent meta-analysis of papers published from
January 1985 to October 2007 concluded that the relative risk
for chronic kidney disease (CKD) and end-stage renal disease
(ESRD) after ARF could not be determined because of a lack
of follow-up of appropriate non-ARF controls.14,15
We recently completed an analysis of hospitalized patients
with a preadmission-estimated glomerular filtration rate
(GFR) o45 ml/min per 1.73 m2, and found that dialysis-
requiring ARF superimposed on preexisting CKD was
associated with a very high risk of precipitating ESRD.16 In
this study, we focused on investigating long-term renal
outcomes in the much larger population of patients with
a normal or near normal kidney function. Specifically,
we compared outcomes among hospitalized patients who
had preadmission baseline-estimated GFRX45 ml/min per
1.73 m2 who did or did not suffer dialysis-requiring ARF. We
hypothesized that, although most patients who suffered
dialysis-requiring ARF and survived hospitalization would
recover sufficient kidney function to become dialysis
independent, they are at an increased long-term risk of
developing progressive CKD.
RESULTS
Patient characteristics
We identified 562,799 patients who had an index hospitaliza-
tion during 1996–2003 with a preadmission-estimated
GFRX45 ml/min per 1.73 m2. There were 703 patients who
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suffered dialysis-requiring ARF, among whom 295 died
(42%) and 65 survived but failed to regain sufficient renal
function to become dialysis independent (9%). Thus, 343
patients survived and did not have ESRD within 30 days of
hospitalization (49%) (Figure 1). Of the 562,076 hospitalized
patients with baseline-estimated GFRX45 ml/min per
1.73 m2 who did not experience dialysis-requiring ARF,
555,660 survived to discharge and did not develop ESRD
within 30 days of hospitalization (99%) (Figure 1).
The median time lapse between the last outpatient serum
creatinine measurement and index hospital admission was 60
days (interquartile range 9–235 days) for those who suffered
ARF and 71 days (interquartile range 6–251) for those who did
not. Table 1 shows the characteristics of the 703 patients who
suffered ARF during hospitalization, the 343 non-ESRD
survivors among them and the 3430 matched non-ARF patients.
Dialysis-requiring
acute kidney injury
N = 703
Survived index
hospitalization
N = 408
Inpatient death
N = 295
No dialysis-requiring
acute kidney injury
N = 562,076
Inpatient death
N = 6416
Survived index
hospitalization
N = 555,682
ESRD
N = 65 Dialysis free at
30 days
N = 555,660
Selectively
matched (10:1)
N = 3430
ESRD
N = 22
Dialysis free at
30 days
N = 343
Figure 1 |Outcomes among 562,779 hospitalized patients
with preadmission estimated glomerular filtration rate
(GFR)X45ml/min per 1.73m2. ESRD, end-stage renal disease.
Table 1 | Characteristics of patients with pre-admission-estimated GFR X45ml/min per 1.73m2 who suffered
dialysis-requiring ARF during hospitalization, the survivors among them, and matched non-ARF patients
Characteristic
Patients who suffered ARF
during hospitalization
(N¼ 703)
ARF survivors who did not start on
dialysis within 30 days of
discharge (N¼ 343)
Matched hospitalization
survivors who did not
suffer ARF (N¼ 3430)
Mean±s.d. age at admission, year 63.5±14.8 62.3±15.3 62.6±15.5
Women, n (%) 275 (39%) 131 (38%) 1310 (38%)
Race/ethnicity
White/European 475 (67.6%) 228 (66.5%) 2280 (66.5%)
Black/African American 95 (13.5%) 40 (11.7%) 400 (11.7%)
Hispanic 43 (6.1%) 27 (7.9%) 270 (7.9%)
Asian/Pacific Islander 50 (7.1%) 25 (7.3%) 250 (7.3%)
Other/unknown 40 (5.7%) 23 (6.7%) 230 (6.7%)
Selected medical history, n (%)
Diabetes mellitus 237 (34%) 111 (32 %) 1110 (32%)
Diagnosed hypertension 404 (57%) 190 (55%) 1587 (46%)
Known proteinuria 220 (31%) 104 (30%) 513 (15%)
Coronary heart disease 241 (34%) 113 (33%) 658 (19%)
Stroke or transient
ischemic attack
114 (16%) 48 (14%) 279 (8%)
Peripheral artery disease 146 (21%) 67 (20%) 234 (7%)
Chronic heart failure 206 (29%) 93 (27%) 255 (7%)
Dyslipidemia 306 (44%) 151 (44%) 1148 (34%)
Chronic lung disease 236 (34%) 116 (34%) 816 (24%)
Chronic liver disease 66 (9%) 25 (7%) 63 (2%)
Cancer 154 (22%) 68 (20%) 439 (13%)
Hypoalbuminemia 305 (43%) 134 (39%) 137 (4%)
Diagnosed dementia 22 (3%) 8 (2%) 106 (3%)
Reasons for hospitalization
Cardiovascular 145 (21%) 61 (18%) 540 (16%)
Respiratory 69 (10%) 21 (6%) 138 (4%)
Gastrointestinal 52 (7%) 24 (7%) 429 (13%)
Infectious disease 65 (9%) 34 (10%) 46 (1%)
Cancer 50 (7%) 17 (5%) 322 (9%)
Lab test before the index hospitalization
Serum creatinine, mg per 100ml
(mean±s.d.)
1.1±0.3 1.1±0.3 1.1±0.3
Estimated GFR, ml/min
per 1.73m2, n (%)
GFR 45–59 234 (33%) 110 (32%) 1100 (32%)
GFR 60–89 312 (44%) 147 (43%) 1470 (43%)
GFRX90 157 (22%) 86 (25%) 860 (25%)
ARF, acute renal failure; GRF, glomerular filtration rate.
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Among the 703 ARF cases, a review of medical records
among a random sample of 100 by a board-certified
nephrologist confirmed that all patients indeed experienced
ARF. The etiologies of ARF for these 100 random cases are
shown in Table 2 and are comparable with that reported in
earlier studies.8
Long-term patient and renal survival
During 10,344 person-years of follow-up, 322 patients
developed progressive CKD, including 281 cases of observed
estimated GFR o30 ml/min per 1.73 m2, and 41 cases of
ESRD. The event rate for progressive CKD was 47.9 per 100
person-years for ARF patients and 1.7 per 100 person-years
for non-ARF patients (Figure 2). It is noteworthy that all 41
ESRD cases occurred among patients who suffered ARF.
We found in a multivariable Cox regression analysis that,
independent of baseline-estimated GFR, age, sex, race/
ethnicity, diabetes mellitus, diagnosed hypertension, and
documented proteinuria, an episode of dialysis-requiring
ARF was associated with a 28-fold increase in the risk of
future progressive CKD (adjusted hazard ratio 28.1; 95% CI
21.1–37.6).
All sensitivity analyses showed similar results. Adjusted
relative risks (hazard ratios) were 28.6 (95% CI 20.2–40.4)
when outcome was changed to time to second observed
estimated GFRo30 ml/min per 1.73 m2 or ESRD; 20.7 (95%
CI 14.7–29.0) after excluding GFR values observed within
6 months after discharge; 24.7 (95% CI 16.9–36.2) after
excluding GFR values observed within 12 months after
discharge; 25.5 (95% CI 18.1–35.9) after adjusting for
baseline comorbidities and reason for hospitalization.
Among patients with baseline-estimated GFRX60 ml/min
per 1.73 m2, adjusted relative risk for progressive CKD was
54.0 (95% CI 34.3–85.1); for patients with baseline-estimated
GFR of 45–59 ml/min per 1.73 m2, it was 13.7 (95% CI
9.1–20.7).
In a secondary analysis with death as the primary outcome
(total number of deaths was 508), an episode of dialysis-
requiring ARF was also independently associated with long-
term risk of mortality with an adjusted hazard ratio of 2.3
(95% CI 1.8–3.0).
DISCUSSION
In this large diverse contemporary cohort of patients
receiving usual clinical care, we found that although most
patients who suffered dialysis-requiring ARF and survived
did recover sufficient kidney function to become dialysis
independent in the short run, there was a greatly increased
relative risk of developing progressive CKD (including
ESRD) in the months to years after hospital discharge.
Furthermore, ARF was independently associated with an
increased risk of long-term mortality.
The underlying mechanism of the manner in which ARF
leads to progressive CKD is not completely understood. But
renal parenchymal injury sustained during episodes of ARF
may lead to permanent tubulointerstitial fibrosis and a
reduction in the number of functioning nephrons. Further-
more, an episode of ARF may—on the basis of animal
models—lead to permanent damage to the renal micro-
vasculature, and trigger inflammatory and fibrotic signaling
pathways that predispose to future accelerated declines in
GFR.17–23
As alluded to earlier, until last year, basically all previous
studies of renal outcomes after ARF were limited by their case
series design and lack of non-ARF comparison indivi-
duals.14,15 They also often had limited generalizability
because of the nature of the patients studied (for example,
only patients treated with continuous renal replacement
therapies24 or only those who were in an intensive care
unit).25,26 Recently, Ishani et al.27 showed among Medicare
beneficiaries (aged X67 years) that ARF was independently
associated with the future development of ESRD with an
adjusted hazard ratio of 13 in the absence of documented
CKD. However, both CKD and ARF were determined in that
study using administrative diagnostic codes that are known
to be insensitive and suffer from ‘code creep’ bias.28,29 Hence,
it is not possible to assess the degree to which their
observation was confounded by, for example, the level of
Table 2 | Diagnoses given for ARF by random chart review
(N¼ 100)
Diagnosis
Decreased renal perfusion (including volume
contraction, congestive heart failure, hypotension,
and cardiac arrest)
49
Medication-related 22
Radiocontrast media 7
Post-operative 13
Sepsis 27
Others 21
ARF, acute renal failure.
Sum exceeds 100 because some cases had more than 1 contributing etiology.
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Figure 2 |Kaplan–Meier curves showing long-term risk of
progressive chronic kidney disease (CKD) (stage 4 or higher)
among patients who did (dashed line) or did not (solid line)
suffer acute renal failure.
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pre-ARF renal dysfunction,30 as patients with lower GFR are
more likely to develop both ARF31 and ESRD.32 Newsome
et al.33 showed that among elderly Medicare patients
suffering from acute myocardial infarction, in-hospital acute
changes in serum creatinine (peak vs first inpatient serum
creatinine) were independently associated with long-term
risk of ESRD. However, residual confounding remains a
concern, given their finding that seemingly minimal changes
in serum creatinine concentration (0.1 mg per 100 ml)
increased future risk of ESRD by as much as 45%, even after
multivariable adjustment.
Our study extends this literature in several important
ways. Our study population was more diverse in terms of age
and underlying disease, and hence our results should be more
generalizable. We used actual observed outpatient (cali-
brated) serum creatinine levels to define baseline kidney
function. We were able to provide a more comprehensive
view of the sequelae of ARF by obtaining data not only on
ESRD27,33 but also on cases of progressive CKD (estimated
GFR o30 ml/min per 1.73 m2). The magnitude of renal
injury was clearly defined and chart validation was performed
to validate the ascertainment of ARF (100% positive
predictive value). We chose to study ARF episodes of
sufficient severity (requiring dialysis) in which there would
be a pathophysiological likelihood of a permanent residual
renal parenchymal damage. We used matching, in addition to
regression, models to adjust for potential confounding.30
Finally, we conducted a series of sensitivity analyses that
enhance our confidence in the robustness of the reported
effect sizes.
Our findings have important public health and population
epidemiology implications. The incidence of ARF has
increased substantially over the past few decades.3–5 We
previously documented the very high risk of ESRD after acute
chronic renal failure16 and we now show that, among the
much larger number of patients with a preexisting normal or
near normal kidney function, dialysis-requiring ARF greatly
increases the risk of subsequent progressive CKD. These
trends may help to explain the somewhat paradoxical
observation that growth in the incidence of treated ESRD
in the United States has outpaced growth in the prevalence of
CKD,34 as well as in the prevalence of risk factors for kidney
failure such as diabetes mellitus.35 Our findings show that the
array of clinical consequences of ARF extends long after
hospitalization.36 Moreover, if successful strategies of ARF
prevention could be developed, they may reduce the
incidence of ESRD.37
From a research point of view, future studies of
interventions in ARF should examine not only inpatient
outcomes38–40 but also extend follow-up beyond discharge to
evaluate the impact of different treatment strategies on the
subsequent level of kidney function (beyond the absence of
dialysis dependency). Our study also contributes toward a
novel insight into risk factors for ESRD. It is noteworthy that
over an 8-year period of follow-up, we did not observe any
cases of ESRD among patients who had baseline-estimated
GFRX45 ml/min per 1.73 m2, unless there was superimposed
dialysis-requiring ARF. Studies on ESRD risk factors in the
past have not considered the role of ARF,32,41–43 but the very
high relative risk associated with ARF merits it being
included among other more established ESRD risk factors,
such as hypertension or diabetes.
Our findings also have important clinical implications.
Given these data, ARF should not be viewed as a transient,
self-limited problem requiring no additional medical atten-
tion after hospital discharge. Currently, only a minority of
patients who suffered ARF are being followed up by
nephrologists or are undergoing testing for evidence of
subtle kidney disease or of risk factors for future loss of
kidney function (such as albuminuria).44 Changing this and
early institution of preventive measures, such as strict blood
pressure control or aggressive renin–angiotensin blockade,
may reduce the high risk of progressive CKD documented
after ARF. Preventing the development of progressive CKD
may also ameliorate the increased risk of death observed
among survivors of ARF, as CKD is a strong and independent
risk factor for cardiovascular disease and overall mortality.45
The limitations of this study need to be mentioned. We
only studied patients who suffered dialysis-requiring ARF.
Hence, we are unable to ascertain the impact of less-severe
degrees of ARF/acute kidney injury. The precise etiology that
led to ARF was not always clear; but it would be unlikely for
dialysis to be needed for reversible pre-renal or post-renal
causes, and the most common cause of intrinsic ARF among
hospitalized patients is acute tubular necrosis.1,2 Our chart
review findings (Table 2) are consistent with this. As our
study was conducted among Kaiser health-plan enrollees, our
results might not be entirely applicable to uninsured patients
or to other health-care settings, although our cohort was
diverse in terms of age, sex, race/ethnicity, and other factors.
We did not obtain information on the graded severity of
proteinuria, which was classified dichotomously. We did not
analyze whether proteinuria or hypertension worsened after
ARF. The observation that the adjusted relative risks for
progressive CKD were greater for higher (X60 ml/min per
1.73 m2) than for lower (46–59 ml/min per 1.73 m2) esti-
mated GFR is due to the low absolute risk of progressive
CKD among those with a more preserved kidney function.
In summary, our findings underscore the important role
of dialysis-requiring ARF in determining the likelihood of
progressive CKD among persons with a normal or near
normal kidney function. Although it has been long
recognized that dialysis-requiring ARF is associated with
short-term inpatient mortality and morbidity, more atten-
tion now needs to be focused on the long-term sequelae of
ARF months to years after hospital discharge.
MATERIALS AND METHODS
Study population
The study population consists of adult members (X20 years old) of
the Kaiser Permanente of Northern California (Kaiser) who were
hospitalized between 1 January 1996 and 31 December 2003 and
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who had a serum creatinine measured before hospitalization, giving
an estimated GFR of X45 ml/min per 1.73 m2 by the Modification
of Diet in Renal Disease equation.46,47
Kaiser is a large integrated health-care delivery system currently
insuring more than 3.2 million individuals in the San Francisco Bay
area. Other than at the extremes of socioeconomic spectrum and
age, wherein there are slightly lower-than-population percentages,
Kaiser membership is highly representative of local surrounding and
statewide populations.48 Relevant coexisting conditions among
Kaiser enrollees can be assessed using comprehensive health-plan
demographic, hospitalization, ambulatory visit, laboratory, pre-
scription medication, and diagnostic code data.45
Assessment of kidney function before and after an ARF
episode
All laboratory tests are financially covered as a part of basic Kaiser
membership benefits. Essentially, all inpatient and outpatient
laboratory test results are performed at or comprehensively obtained
through a central Kaiser regional laboratory. Baseline kidney
function before ARF was defined as estimated GFR from the last
outpatient serum creatinine measurement before hospitalization.
Subsequent kidney function evolution was defined using estimated
GFR values from outpatient serum creatinine measurements
after discharge. We chose to use outpatient serum creatinine
measurements to define baseline kidney function, as these were
more likely to reflect the usual steady state function in the absence
of acute illness.16,30,31 The Kaiser regional health-plan laboratory
had previously calibrated measurement of serum creatinine
against the Modification of Diet in Renal Disease core laboratory
to ensure a more accurate estimate of GFR (applicable to the study
time period 1996–2003).49,50
Identification of exposure: dialysis-requiring ARF
Dialysis-requiring ARF was defined as having a peak inpatient serum
creatinine level higher than the last outpatient serum creatinine
(baseline) level byX50% and a receipt of renal replacement therapy
during hospitalization. Renal replacement therapy including acute
peritoneal dialysis, hemodialysis, or hemofiltration was identified by
the International Classification of Disease, ninth Edition (ICD-9)
procedure codes 54.98 and 39.95 and the Current Procedural
Terminology (CPT) codes 90935, 90937, 90945, 90947, and 90999.
Non-ARF (unexposed) individuals were hospitalized patients
with an outpatient-estimated GFRX45 ml/min per 1.73 m2 docu-
mented from their latest serum creatinine measurement before
admission but who did not suffer dialysis-requiring ARF.
For both ARF and non-ARF patients, we analyzed only the first
hospital admission for each patient, which was preceded by a known
outpatient serum creatinine level after 1 January 1996 (this
admission is referred to as the index hospitalization). Patients who
had ESRD (defined as receipt of kidney transplantation or already
on maintenance dialysis) before index hospitalization were excluded
from further consideration. ESRD status was ascertained by cross-
linking the US Renal Data System (USRDS) and an internal Kaiser
ESRD registry.16,31,51 At the time of cross-linkage, USRDS data were
complete through to 31 December 2003.
Definition of primary outcome: progression to stage 4 or
worse CKD
We determined the proportion of patients who suffered dialysis-
requiring ARF and became dialysis dependent within 30 days of
hospital discharge using USRDS and the internal Kaiser registry.
This classification of cases of ARF immediately precipitating ESRD
was made only after a confirmatory chart review by a board-certified
nephrologist. We chose a 30-day window, given the uncertainty
inherent in the start date of ESRD from both USRDS and Kaiser
ESRD registries. Furthermore, progression to ESRD at the time of
hospital discharge or any time within this 30-day window was
judged to be of similar importance clinically.
Patients who suffered dialysis-requiring ARF, who survived their
index hospitalization, and who did not develop ESRD within 30
days of discharge were then compared with patients who did not
suffer dialysis-requiring ARF, who also survived their index
hospitalization, and remained ESRD-free for 30 days after hospital
discharge. Our primary interest was to compare, between these two
groups, the risk of developing progressive CKD in subsequent
months to years. Progressive CKD was defined as the development
of a subsequent estimated GFRp30 ml/min per 1.73 m2 or ESRD
(that is, stage 4 or higher CKD by the National Kidney Foundation
classification system47). Both were ascertained through to 31
December 2003.
Statistical analysis
Any observed differences in outcome among patients with and
without dialysis-requiring ARF may be due to confounding by
differences in baseline characteristics, such as level of kidney
function, as reduced GFR is a strong predictor of ARF31 and of
even lower GFR or ESRD (and other adverse outcomes).45 We used
matching as one tool to control for confounding.30 Each dialysis-
requiring ARF patient who survived hospitalization and who did not
develop ESRD within 30 days of hospital discharge was matched to
10 hospitalized non-ARF patients on the basis of the following
matching variables: preadmission-estimated GFR level (45–59 ml/
min per 1.73 m2, 60–89 ml/min per 1.73 m2, and X90 ml/min per
1.73 m2), diabetes mellitus (present/absent), age (by 10-year
categories), sex (male/female), and race/ethnicity (White, Black,
Asian or Pacific Islander, Hispanic, Others, or Unknown). A 10:1
ratio was chosen to enhance statistical power, given the large
number of non-ARF individuals available.
We performed survival analysis using Cox proportional hazards
regression censoring for death, disenrollment from health plan, or
end of follow-up on 31 December 2003. We confirmed that the
proportional hazards assumption was not violated by comparing
estimated log (log(survivor function)) vs time (person-years)
survivor curves. We determined the independent association
between ARF and progressive CKD in a Cox model that took into
account the matching design, and also adjusted for diagnosed
hypertension and documented proteinuria. To additionally control
for residual confounding within each age or GFR category, we also
entered age and estimated GFR as linear terms into the regression
model.
We then conducted a series of sensitivity analyses. To avoid
potentially misclassifying low estimated GFR values observed during
recovery after dialysis-requiring ARF as CKD, we repeated our
analysis ignoring any serum creatinine values observed 6 or 12
months after index hospitalization. To be more certain of the
chronicity of the low GFR to establish CKD, we examined time to
the second (confirmed) estimated GFRp30 ml/min per 1.73 m2. To
minimize residual confounding, we additionally adjusted for the
comorbid conditions listed in Table 1 and for major reasons for
hospitalization using primary discharge diagnosis divided generally
into ‘diseases of the circulatory system’ (390–459), ‘diseases of the
respiratory system’ (460–519), ‘diseases of the gastrointestinal
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system’ (520–579), ‘infectious diseases’ (001–139), ‘neoplasms’
(140–239), and all others.16,52 We also conducted a stratified analysis
by baseline-estimated GFR above or below 60 ml/min per 1.73 m2.
In secondary analysis, we examined death as an end point to
determine whether dialysis-requiring ARF was independently
associated with longer-term mortality. Deaths were identified from
health-plan administrative databases and from member proxy
reporting,45 Social Security Administration files,53 and the Califor-
nia Automated Mortality Linkage Information System.54 We used
the same matched cohort design and Cox model that adjusted for
age and estimated GFR as linear terms, as well as for diagnosed
hypertension, documented proteinuria, other comorbid conditions
listed in Table 1, and reason for hospitalization.
Analyses were performed using SAS (Cary, NC, USA). The
institutional review boards of collaborating institutions approved
the study. Waiver of informed consent was obtained because of the
nature of the study.
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